NasdaqCM - Nasdaq Real Time Price USD

BriaCell Therapeutics Corp. (BCTX)

Compare

0.4578

-0.1829

(-28.55%)

At close: January 6 at 4:00:00 PM EST

0.4601

+0.00

(+0.50%)

After hours: 7:58:48 PM EST

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Co

GlobeNewswire 3 days ago

BCTX
-28.55%
BCTXW
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders (the “Meeting”), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wedn

GlobeNewswire 3 days ago

BCTX
-28.55%
BCTXW
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m

Insiders who bought US$5.52m worth of BriaCell Therapeutics Corp.'s ( TSE:BCT ) stock at an average buy price of...

Simply Wall St. 18 days ago

BCTX
-28.55%
BCTXW
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-rel

GlobeNewswire 20 days ago

BCTX
-28.55%
BCTXW
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials

GlobeNewswire 20 days ago

BCTX
-28.55%
BCTXW
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associa

GlobeNewswire 24 days ago

BCTX
-28.55%
BCTXW
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI)Imaging confirms clinical responses seen in metastatic breast cancer correlate with increase in CD8+ “killer” T Cells in lesions and lymph nodes PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell

GlobeNewswire 24 days ago

BCTX
-28.55%
BCTXW
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warra

GlobeNewswire 26 days ago

BCTX
-28.55%
BCTXW
BriaCell Therapeutics Announces Proposed Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares and warrants in an underwritten public offering. All of the common shares and warrants are to be sold by the Company. The offering is subject to market conditions a

GlobeNewswire 26 days ago

BCTX
-28.55%
BCTXW
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literatureFinal Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the studyMedian OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point i

GlobeNewswire 26 days ago

BCTX
-28.55%
BCTXW
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic breast cancerThe pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clini

GlobeNewswire last month

BCTX
-28.55%
BCTXW
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calculation is pending, as many patients remain alivePotential identification of biomarkers to predict responseFive poster presentations to feature increased presence of cancer figh

GlobeNewswire last month

BCTX
-28.55%
BCTXW
BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors, effective immediately. The Board thanks Marc for his strong contributions to the Company over his tenure. About BriaC

GlobeNewswire last month

BCTX
-28.55%
BCTXW
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS™ to be studied as monotherapy and in combination with BeiGene’s anti-PD-1 antibody PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel immunotherapies to transform cancer care, announces that the first patient was

GlobeNewswire last month

BCTX
-28.55%
BCTXW
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates both innate and adaptive immune systemsProof of concept Phase 1/2 Study of Bria-BRES™ in metastatic breast cancer currently underway PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”),

GlobeNewswire last month

BCTX
-28.55%
BCTXW
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company

GlobeNewswire 2 months ago

BCTX
-28.55%
BCTXW
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

PREMIUM
MT Newswires 2 months ago

BCTXW
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple outperforming patients with overall survival of over 2 yearsSurvival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs) Final median overall survival calculation for the Phase 2 study is pending, as many patients

GlobeNewswire 2 months ago

BCTX
-28.55%
BCTXW
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician’s choiceInterim data analysis planned at 144 events (deaths) could provide full approval and marketing authorizationPivotal Phase 3 study patient enrollment completion is expected in mid-2025 No serious adverse events related to

GlobeNewswire 2 months ago

BCTX
-28.55%
BCTXW
BriaCell Therapeutics Announces Closing of $5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering of 5,128,500 common shares and warrants to purchase up to 5,128,500 common shares at a combined offering price of $0.975 per share and associated war

GlobeNewswire 3 months ago

BCTX
-28.55%
BCTXW

Performance Overview

Return	BCTX	S&P/TSX Composite index
YTD	-19.68%	+1.54%
1-Year	-91.51%	+19.40%
3-Year	-94.66%	+18.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BriaCell Therapeutics Corp. (BCTX)

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

BriaCell Therapeutics Announces Proposed Public Offering

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

BriaCell Provides Update to its Board of Directors

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BriaCell Therapeutics Announces Closing of $5 Million Offering

Performance Overview